BioGlena (Beta-glucan from Euglena gracilis)

BioGlena is a proprietary beta-1,3-glucan extracted from Euglena gracilis microalgae that may support immune function through polysaccharide-mediated pathways. The beta-glucan component theoretically activates immune cells by binding to pattern recognition receptors, though clinical evidence remains limited.

Origin & History

BioGlena is a branded ingredient consisting of whole-cell dried biomass from the microalgae Euglena gracilis, containing 50-55% paramylon (linear beta-1,3-glucan) as its primary bioactive compound. It is produced through controlled fermentation in bioreactors, followed by harvesting, centrifugation, and drying methods such as spray drying or freeze drying to yield a non-viable powder.

Historical & Cultural Context

No historical or traditional medicinal use of E. gracilis or its beta-glucan is documented in the available sources. BioGlena represents a modern biotechnology product developed through laboratory-controlled fermentation without traditional usage context.

Health Benefits

• Potential immune system enhancement through beta-1,3-glucan content (evidence quality: theoretical - no clinical trials found)
• May support immune modulation via intestinal immune cell activation (evidence quality: mechanistic hypothesis only)
• Possible priming of innate and adaptive immune responses (evidence quality: manufacturer claims without clinical data)
• Contains complete proteins (≥20%) and essential vitamins/minerals (evidence quality: compositional analysis only)
• GRAS-recognized safety status for food use (evidence quality: regulatory filing, not efficacy data)

How It Works

BioGlena's beta-1,3-glucan binds to dectin-1 and complement receptor 3 (CR3) on macrophages, dendritic cells, and neutrophils. This binding triggers downstream signaling cascades involving Syk kinase and NF-κB pathways, potentially enhancing cytokine production and immune cell activation. The polysaccharide structure may also stimulate intestinal Peyer's patches, influencing both innate and adaptive immune responses.

Scientific Research

No human clinical trials, randomized controlled trials (RCTs), or meta-analyses for BioGlena or E. gracilis beta-1,3-glucan were found in the available research. The evidence consists primarily of patent claims and manufacturer descriptions without supporting PMIDs or published clinical data.

Clinical Summary

Currently, no published clinical trials specifically evaluate BioGlena's immune effects in humans. Available research consists primarily of mechanistic studies on beta-glucan interactions with immune cells in laboratory settings. While other beta-glucan sources show immune benefits in clinical studies, direct evidence for Euglena gracilis-derived beta-glucan remains theoretical. More human trials are needed to validate proposed immune-enhancing properties and establish effective dosing protocols.

Nutritional Profile

BioGlena (Beta-glucan from Euglena gracilis) is a concentrated bioactive ingredient with the following characterized components: Primary bioactive compound is beta-1,3-glucan (paramylon) at approximately 50-65% dry weight, a highly crystalline linear polysaccharide unique to Euglena gracilis distinguishing it from yeast or oat-derived beta-glucans. Protein content is notable at approximately 40-60% dry weight on a whole Euglena basis (though concentrated paramylon extracts are predominantly polysaccharide), containing all essential amino acids including lysine and methionine, qualifying as a complete protein source. Lipid content includes wax esters and polyunsaturated fatty acids, notably EPA (eicosapentaenoic acid) at trace to moderate levels depending on cultivation conditions. Micronutrient profile includes vitamin B12 (approximately 1-2 mcg per gram in whole biomass), vitamin C, vitamin E (alpha-tocopherol), iron (approximately 6-9 mg/100g), zinc, and magnesium. Chlorophyll derivatives are present in whole-cell preparations. Bioavailability note: Paramylon in its native crystalline form has relatively low digestibility in humans (~15-30%) compared to solubilized or processed forms; enzymatic or thermal processing can significantly increase functional bioavailability. The beta-1,3-glucan structure binds to Dectin-1 receptors on immune cells, a mechanistically relevant interaction not dependent on full digestion.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials are absent. BioGlena is standardized to approximately 55% linear beta-1,3-glucan content in whole biomass powder form. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vitamin C, Vitamin D3, Zinc, Elderberry Extract, Probiotics

Safety & Interactions

BioGlena appears generally well-tolerated based on the safety profile of similar beta-glucan compounds, though specific toxicity data is limited. Potential side effects may include mild gastrointestinal upset, particularly at higher doses. Individuals with autoimmune conditions should exercise caution, as immune stimulation could theoretically exacerbate symptoms. Safety during pregnancy and lactation has not been established, and potential interactions with immunosuppressive medications warrant medical supervision.